Related references
Note: Only part of the references are listed.Real-world experience of using ciclosporin-A 0.1% (Ikervis) in the management of ocular surface inflammatory diseases
Rashmi Deshmukh et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2022)
Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases
Philippe Daull et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2022)
Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment
Gerd Geerling et al.
OPHTHALMOLOGY AND THERAPY (2022)
Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjogren's Syndrome
Jonghwa Kim et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2021)
Twelve-Month Results of Cyclosporine A Cationic Emulsion in a Randomized Study in Patients With Pediatric Vernal Keratoconjunctivitis
Dominique Bremond-Gignac et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2020)
The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options
Laura M. Periman et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2020)
Defining Dry Eye from a Clinical Perspective
Kazuo Tsubota et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
Laura M. Periman et al.
CLINICAL OPHTHALMOLOGY (2020)
Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
Bridgitte Shen Lee et al.
CLINICAL OPHTHALMOLOGY (2020)
Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies
Andrea Leonardi et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2019)
Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease
Jennifer Hind et al.
EYE (2019)
Dry Eye Syndrome Preferred Practice Pattern®
Esen K. Akpek et al.
OPHTHALMOLOGY (2019)
A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis
Andrea Leonardi et al.
OPHTHALMOLOGY (2019)
Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
Rodrigo Carlos de Oliveira et al.
CLINICAL OPHTHALMOLOGY (2019)
Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
Darrell E. White et al.
CLINICAL OPHTHALMOLOGY (2019)
Evaluating the novel application of cyclosporine 0.1% in ocular surface disease
Konstadinos G. Boboridis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study
Marc Labetoulle et al.
CLINICAL THERAPEUTICS (2018)
Conjunctival Inflammatory Gene Expression Profiling in Dry Eye Disease: Correlations With HLA-DRA and HLA-DRB1
Karima Kessal et al.
FRONTIERS IN IMMUNOLOGY (2018)
Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
Tatiana Deveney et al.
CLINICAL OPHTHALMOLOGY (2018)
Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
Pierre-Jean Pisella et al.
CLINICAL OPHTHALMOLOGY (2018)
One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease
Christophe Baudouin et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2017)
TFOS DEWS II Management and Therapy Report
Lyndon Jones et al.
OCULAR SURFACE (2017)
TFOS DEWS II Definition and Classification Report
Jennifer P. Craig et al.
OCULAR SURFACE (2017)
The Pathophysiology of Dry Eye Disease What We Know and Future Directions for Research
Stephen C. Pflugfelder et al.
OPHTHALMOLOGY (2017)
Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease
Sheridan M. Hoy
DRUGS (2017)
Increased corneal sub-basal nerve density in patients with Sjogren syndrome treated with topical cyclosporine A
Ora Levy et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up
Morgane Straub et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction
Christophe Baudouin et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial
Andrea Leonardi et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2016)
Role of Hyperosmolarity in the Pathogenesis and Management of Dry Eye Disease: Proceedings of the OCEAN Group Meeting
Christophe Baudouin et al.
OCULAR SURFACE (2013)
Share Paper
